Trial Profile

Phase II Trial of Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Lapatinib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

Most Recent Events

06 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Apr 2017.
06 Feb 2017 Status changed from completed to active, no longer recruiting.
24 Oct 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com